Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.5616-0.0484 (-7.93%)
At close: 04:00PM EDT
0.6277 +0.07 (+11.77%)
After hours: 04:16PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.6100
Open0.5700
Bid0.5530 x 1100
Ask0.6300 x 800
Day's Range0.5616 - 0.6299
52 Week Range0.5160 - 1.3900
Volume13,199
Avg. Volume22,066
Market Cap21.31M
Beta (5Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)-0.2450
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AgeX Therapeutics, Inc.
    ACA: Lowering target price to $62.00ARCOSA INC has an Investment Rating of BUY; a target price of $62.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Business Wire

    AgeX Therapeutics Reports Second Quarter 2022 Financial Results

    ALAMEDA, Calif., August 12, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.

  • Business Wire

    Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

    ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2022 Financial Results

    ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

Advertisement
Advertisement